Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses

- Johnson & Johnson (NYSE: JNJ) (the Company) today announced preliminary results from an independent study, including a subset of participants from the Janssen-sponsored COV2008 study, conducted by Dan Barouch M.D., Ph.D., et al. of Beth Israel Deaconess Medical Center (BIDMC), which showed that a booster shot of the Johnson & Johnson COVID-19 vaccine (Ad26.COV2.S), administered at six months after a two-dose primary regimen of BNT162b2, increased both antibody and T-cell responses. These results demonstrate the potential benefits of heterologous boosting (mix-and-match). The article describing these results have been posted on medRxiv .

"There is early evidence to suggest that a mix-and-match boosting approach may provide individuals with different immune responses against COVID-19 than a homologous boosting approach," said Dan Barouch , M.D., Ph.D., Director of the Center for Virology and Vaccine Research at BIDMC. "In this preliminary study, when a booster dose of Ad26.COV2.S was given to individuals six months after a primary regimen with the BNT162b2 vaccine, there was a comparable increase of antibody responses at week four following the boost and a greater increase of CD8+ T-cell responses with Ad26.COV2.S compared with BNT162b2."

Keep reading... Show less

Kart Racing League by Blue Monster Games Inc. announces listing on BitMart ahead of game launch

Fast-rising play-to-earn NFT game Kart Racing League has announced the listing of its governance token, KRL, on top centralized exchange BitMart. KRL will be available for trading in BitMart starting December 6, 2021 ahead of the much-anticipated release of the Kart Racing League game which will be fully-released on December 10 . The game was developed by Blue Monster Games Inc. (BMG), a Florida -based company that specializes in the development of unique NFT games. This marks the company's first major listing.

In a statement, BMG CEO Joseph Rubin said: "After successful KRL listings on the decentralized exchanges Sushiswap and Quickswap, we are excited to move to the next stage of our roadmap by listing on a centralized exchange and the choice of BitMart is a no-brainer. BitMart is a massive exchange with over 5 million registered users and billions in trading volume and KRL can benefit massively from this exposure."

Keep reading... Show less

Bristol Myers 48 Hour Deadline Alert: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits against Bristol-Myers Squibb Company - BMY

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 6, 2021 to file lead plaintiff applications in securities class action lawsuits against Bristol-Myers Squibb Company ("BMS" or "the Company") (NYSE:BMY), if they received Contingent Value Rights ("CVRs") in exchange for their shares of Celgene Corporation pursuant to BMS' acquisition of Celgene on November 20, 2019. These actions are pending in the United States District Court for the Southern District of New York

What You May Do

Keep reading... Show less

CRON INVESTOR NOTICE: ROSEN, A LEADING NATIONAL FIRM, Encourages Cronos Group Inc. Investors with Losses to Inquire About Class Action Investigation - CRON

-

Keep reading... Show less

Cohen Milstein Files Class Action Complaint Against Bristol-Myers Squibb Company

Cohen Milstein Sellers & Toll PLLC ("Cohen Milstein") today announced that its ongoing investigation has led to the filing of a class action complaint against Bristol-Myers Squibb Company ("Bristol Myers") and several of its senior executives and directors. The case was filed in the United States District Court for the Southern District of New York, Case No. 21-cv-10351

The action was brought on behalf of all former Celgene Corporation ("Celgene") (CELG) shareholders that received Contingent Value Rights ("CVRs") in exchange for their Celgene shares pursuant to Bristol Myers' $74 billion acquisition of Celgene on November 20, 2019, and were damaged thereby, and all persons who purchased CVRs between November 20, 2019 and December 31, 2020 (the "Class Period"), and who were damaged thereby (the "Class").

Keep reading... Show less

BRISTOL MYERS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Bristol-Myers Squibb Company - BMY

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 6, 2021 to file lead plaintiff applications in securities class action lawsuits against Bristol-Myers Squibb Company ("BMS" or "the Company") (NYSE: BMY), if they received Contingent Value Rights ("CVRs") (NYSE: BMY.RT) in exchange for their shares of Celgene Corporation (NASDAQ: CELG) pursuant to BMS' acquisition of Celgene on November 20, 2019. These actions are pending in the United States District Court for the Southern District of New York.

What You May Do

Keep reading... Show less

Top News

Related News